Biased Ligands. Better Drugs.

Biased Ligand Products

Cardiovascular Program

Although Trevena's biased GPCR ligand technology is potentially applicable across a wide range of drug targets and diseases, our pipeline of wholly owned differentiated biased ligand drugs is currently focused on CNS diseases.

Recent Product News

Related Events

  • 13th Annual ASRA Pain Medicine Meeting, San Francisco, California11/13/2014 - 11/16/2014

    Dr. Michael Lark, CSO, will be attending the American Society of Regional Anesthesia and Pain 13th Annual Pain Medicine Meeting in San Francisco, California from 13th to 16th of November 2014.

    Details on the meeting, can be found at the ASRA website.

  • AHA Scientific Sessions, Chicago, Illinois11/15/2014 - 11/19/2014

    Dr. David Soergel, SVP Clinical Development and Ms. Kathy Goin, VP, Clinical Operations, will be attending the AHA Scientific Sessions in Chicago, Illinois. The event will take place between November 15 - 19 at the McCormick Place convention center.

Copyright © Trevena, Inc.